178 related articles for article (PubMed ID: 33649104)
1. Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Wang Y; Pandey RN; Roychoudhury K; Milewski D; Kalin TV; Szabo S; Pressey JG; Hegde RS
Mol Cancer Ther; 2021 May; 20(5):803-815. PubMed ID: 33649104
[No Abstract] [Full Text] [Related]
2. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of EYA3 Protein in Ewing Sarcoma.
Shah FH; Kim SJ
Asian Pac J Cancer Prev; 2022 May; 23(5):1539-1545. PubMed ID: 35633536
[TBL] [Abstract][Full Text] [Related]
4. EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.
Gallegos ZR; Taus P; Gibbs ZA; McGlynn K; Gomez NC; Davis I; Whitehurst AW
Mol Cell Biol; 2019 Jul; 39(14):. PubMed ID: 31036566
[TBL] [Abstract][Full Text] [Related]
5. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
7. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
8. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
9. The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.
Wang Y; Pandey RN; Riffle S; Chintala H; Wikenheiser-Brokamp KA; Hegde RS
Mol Cancer Ther; 2018 Aug; 17(8):1659-1669. PubMed ID: 29802120
[TBL] [Abstract][Full Text] [Related]
10. Primary subcutaneous spindle cell Ewing sarcoma with strong S100 expression and EWSR1-FLI1 fusion: a case report.
Arnold MA; Ballester LY; Pack SD; Abdullaev Z; Merchant M; Tsokos MG
Pediatr Dev Pathol; 2014; 17(4):302-7. PubMed ID: 24735198
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
12. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
13. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
[TBL] [Abstract][Full Text] [Related]
14. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
15. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
16. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
18. Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.
Yeung C; Gibson AE; Issaq SH; Oshima N; Baumgart JT; Edessa LD; Rai G; Urban DJ; Johnson MS; Benavides GA; Squadrito GL; Yohe ME; Lei H; Eldridge S; Hamre J; Dowdy T; Ruiz-Rodado V; Lita A; Mendoza A; Shern JF; Larion M; Helman LJ; Stott GM; Krishna MC; Hall MD; Darley-Usmar V; Neckers LM; Heske CM
Cancer Res; 2019 Oct; 79(19):5060-5073. PubMed ID: 31431459
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
[TBL] [Abstract][Full Text] [Related]
20. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
